- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Pfizer Launches Trastuzumab Biosimilar
With Trazimera in place, Herceptin now has 3 biosimilar competitiors.
Pfizer's trastuzumab biosimilar to Herceptin, Trazimera, launched Wednesday in the United States.
Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
The company said last month that Trazimera will have a wholesale acquisition cost (WAC) of $80.74 per 10 mg, a 22% discount to the WAC of Herceptin. In January, Pfizer launched its rituximab product, Ruxience (referencing Rituxan), and its biosimilar bevacizumab Zirabev (referencing Avastin).
With Trazimera in place, Herceptin now has 3 biosimilar competitiors. Besides Trazimera, the other 2 are the Mylan and Biocon biosimilar trastuzumab, Ogivri, and Amgen’s Kanjinti. Both launched last year.
This is the sixth biosimilar to launch within 120 days, making for 15 biosimilars launched in the U.S. The launch of Trazimera officially makes the Herceptin market one of the most competitive therapeutic markets in the U.S. (now having three biosimilars competing with one reference product) and the Herceptin market could have as many as five biosimilars competing in it by the end of 2020
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
March 19th 2025Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.
